ArticleFrontiers in neurology2025
Serum biomarkers and postherpetic neuralgia in herpes zoster patients with immunocompetent.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nomogram-Based Prediction Model for Postherpetic Neuralgia in Immunosuppressive Patients.Journal of clinical medicine · 2026Article
- Unraveling immune-inflammation-aging network interactions: an interpretable machine learning model predicts the risk of postherpetic neuralgia.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postherpetic neuralgia (PHN) typically occurs in immunocompromised patients. However, there is a lack of prospective studies involving large samples of immunocompetent individuals. A prospective study was conducted to ascertain the association between serum levels of various markers and the occurrence of PHN in acute herpes zoster (HZ) patients with immunocompetent. Methods: A total of 887 acute HZ patients with immunocompetent who were admitted to Hangzhou Third People's Hospital between April 2021 and December 2023 were selected. Peripheral venous blood at their initial visit was collected and the levels of various serum markers were detected. According to whether PHN occurred or not during follow-up, the participants were divided into PHN group and non-PHN group. Multivariate logistic regression analysis was used to screen the influencing factors of PHN. Results: Two hundred and seventeen cases (24.5%) developed PHN. Compared with the non-PHN group, age, numerical rating scale (NRS) scores, levels of C reactive protein (CRP) and homocysteine (HCY) in PHN group were significantly increased ( Conclusion: Age and the severity of pain at the time of onset were also the risk factors for PHN in acute HZ patients with immunocompetent. The levels of serum CRP and HCY as potential biomarkers may have certain reference value for predicting the occurrence of PHN in acute HZ patients with immunocompetent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.